282 related articles for article (PubMed ID: 9316026)
1. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus).
Taylor JR; Elsworth JD; Roth RH; Sladek JR; Redmond DE
Neuroscience; 1997 Dec; 81(3):745-55. PubMed ID: 9316026
[TBL] [Abstract][Full Text] [Related]
2. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
[TBL] [Abstract][Full Text] [Related]
3. Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls.
Taylor JR; Elsworth JD; Roth RH; Sladek JR; Collier TJ; Redmond DE
Exp Brain Res; 1991; 85(2):335-48. PubMed ID: 1893983
[TBL] [Abstract][Full Text] [Related]
4. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
[TBL] [Abstract][Full Text] [Related]
5. Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs.
Wade TV; Schneider JS
J Neurosci; 2001 Jul; 21(13):4901-7. PubMed ID: 11425917
[TBL] [Abstract][Full Text] [Related]
6. Developing a stable bilateral model of parkinsonism in rhesus monkeys.
Smith RD; Zhang Z; Kurlan R; McDermott M; Gash DM
Neuroscience; 1993 Jan; 52(1):7-16. PubMed ID: 8433810
[TBL] [Abstract][Full Text] [Related]
7. Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.
Goldberg JA; Boraud T; Maraton S; Haber SN; Vaadia E; Bergman H
J Neurosci; 2002 Jun; 22(11):4639-53. PubMed ID: 12040070
[TBL] [Abstract][Full Text] [Related]
8. Physiology of MPTP tremor.
Bergman H; Raz A; Feingold A; Nini A; Nelken I; Hansel D; Ben-Pazi H; Reches A
Mov Disord; 1998; 13 Suppl 3():29-34. PubMed ID: 9827591
[TBL] [Abstract][Full Text] [Related]
9. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Albanese A; Granata R; Gregori B; Piccardi MP; Colosimo C; Tonali P
Neuroscience; 1993 Aug; 55(3):823-32. PubMed ID: 8105418
[TBL] [Abstract][Full Text] [Related]
10. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.
Bezard E; Imbert C; Deloire X; Bioulac B; Gross CE
Brain Res; 1997 Aug; 766(1-2):107-12. PubMed ID: 9359593
[TBL] [Abstract][Full Text] [Related]
11. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
[TBL] [Abstract][Full Text] [Related]
12. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.
Bergman H; Wichmann T; Karmon B; DeLong MR
J Neurophysiol; 1994 Aug; 72(2):507-20. PubMed ID: 7983515
[TBL] [Abstract][Full Text] [Related]
13. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
Lange KW
Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
[TBL] [Abstract][Full Text] [Related]
14. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
15. Cognitive and motor deficits in the performance of an object retrieval task with a barrier-detour in monkeys (Cercopithecus aethiops sabaeus) treated with MPTP: long-term performance and effect of transparency of the barrier.
Taylor JR; Roth RH; Sladek JR; Redmond DE
Behav Neurosci; 1990 Aug; 104(4):564-76. PubMed ID: 2206426
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study.
Elsworth JD; Brittan MS; Taylor JR; Sladek JR; Redmond DE; Innis RB; Zea-Ponce Y; Roth RH
Brain Res; 1998 Jun; 795(1-2):55-62. PubMed ID: 9622593
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions.
Elsworth JD; Deutch AY; Redmond DE; Taylor JR; Sladek JR; Roth RH
Neuroscience; 1989; 33(2):323-31. PubMed ID: 2622529
[TBL] [Abstract][Full Text] [Related]
18. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Nishi K; Kondo T; Narabayashi H
No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
[TBL] [Abstract][Full Text] [Related]
19. Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Tetrud JW; Langston JW; Garbe PL; Ruttenber AJ
Neurology; 1989 Nov; 39(11):1483-7. PubMed ID: 2812327
[TBL] [Abstract][Full Text] [Related]
20. Subthalamotomy improves MPTP-induced parkinsonism in monkeys.
Guridi J; Herrero MT; Luquin R; Guillen J; Obeso JA
Stereotact Funct Neurosurg; 1994; 62(1-4):98-102. PubMed ID: 7631095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
